



2020

1. Kalkowska DA, Thompson KM. Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan. *Risk Anal* 2020. doi:10.1111/risa.13471. <https://pubmed.ncbi.nlm.nih.gov/32144841/>. Epub 2020 Mar 6.
2. Badizadegan K, Goodson JL, Rota PA, Thompson KM. The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization. *Expert Rev Vaccines* 2020; **19**(2): 175-94. doi:10.1080/14760584.2020.1732215. <https://www.ncbi.nlm.nih.gov/pubmed/32182145>. Epub 2020 Mar 17.
3. Thompson KM, Orenstein WA, Hinman AR. Performance of the United States Vaccine Injury Compensation Program (VICP): 1988–2019. *Vaccine* 2020. doi: 10.1016/j.vaccine.2020.01.042. <https://doi.org/10.1016/j.vaccine.2020.01.042>. Epub 2020 Jan 22.
4. Kalkowska DA, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Global transmission of live polioviruses: Updated dynamic modeling of the polio endgame. *Risk Anal* 2020. doi: 10.1111/risa.13447. <https://www.onlinelibrary.wiley.com/doi/10.1111/risa.13447>. Epub 2020 Jan 20.
5. Vanlandingham DM, Hampton W, Thompson KM, Badizadegan K. Modeling pathology workload and complexity to manage risks and improve patient quality and safety. *Risk Anal* 2020; **40**(2): 421-34. doi:10.1111/risa.13393. <https://www.ncbi.nlm.nih.gov/pubmed/31476083>. Epub 2019 Sep 2.

2019

6. Thompson KM, Kalkowska DA. Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV). *Expert Rev Vaccines* 2019; **18**(7): 725-36. doi:10.1080/14760584.2019.1635463. <https://www.ncbi.nlm.nih.gov/pubmed/31248293>
7. Thompson KM. What will it take to end fatalities from measles? *Lancet Glob Health* 2019; **7**(4): e394-e5. doi:10.1016/s2214-109x(19)30050-6. <https://www.ncbi.nlm.nih.gov/pubmed/30797736>
8. Thompson KM. Polio endgame options: will we have the vaccines needed? *Lancet* 2019; **394**(10193): 99-100. doi:10.1016/S0140-6736(19)31294-2. <https://www.ncbi.nlm.nih.gov/pubmed/31174833>
9. Kalkowska DA, Pallansch MA, Thompson KM. Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excretors. *Epidemiol Infect* 2019; **147**: e295. doi:10.1017/s095026881900181x. <https://www.ncbi.nlm.nih.gov/pubmed/31647050>
10. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation. *Risk Anal* 2019; **39**(2): 414-25. doi:10.1111/risa.13193. <https://www.ncbi.nlm.nih.gov/pubmed/30239023>
11. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan. *Risk Anal* 2019; **39**(2): 402-13. doi:10.1111/risa.13214. <https://www.ncbi.nlm.nih.gov/pubmed/30296340>
12. Duintjer Tebbens RJ, Thompson KM. Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan. *Risk Anal* 2019; **39**(2): 389-401. doi:10.1111/risa.13194. <https://www.ncbi.nlm.nih.gov/pubmed/30239026>
13. Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM. Characterising the costs of the global polio laboratory network: a survey-based analysis. *BMJ Open* 2019; **9**(1): e023290. doi:10.1136/bmjopen-2018-023290. <https://www.ncbi.nlm.nih.gov/pubmed/30670511>



2018

14. Tebbens RJD, Kalkowsa DA, Thompson KM. Poliovirus containment risks and their management. *Future Virology* 2018; **13**(9): 617-28. doi:10.2217/fvl-2018-0079. <https://www.futuremedicine.com/doi/abs/10.2217/fvl-2018-0079>
15. Ozawa S, Yemeke TT, Thompson KM. Systematic review of the incremental costs of interventions that increase immunization coverage. *Vaccine* 2018; **36**(25): 3641-9. doi:10.1016/j.vaccine.2018.05.030. <https://www.ncbi.nlm.nih.gov/pubmed/29754699>
16. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Another look at silent circulation of poliovirus in small populations. *Infect Dis Model* 2018; **3**: 107-17. doi:10.1016/j.idm.2018.06.001. <https://www.ncbi.nlm.nih.gov/pubmed/30839913>
17. Duintjer Tebbens RJ, Thompson KM. Using integrated modeling to support the global eradication of vaccine-preventable diseases. *System Dynamics Review* 2018; **34**(1-2): 78-120. doi:10.1002/sdr.1589. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sdr.1589>
18. Duintjer Tebbens RJ, Thompson KM. Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine. *Expert Rev Vaccines* 2018; **17**(8): 739-51. doi:10.1080/14760584.2018.1506333. <https://www.ncbi.nlm.nih.gov/pubmed/30056767>
19. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM. Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations. *Risk Anal* 2018; **38**(8): 1701-17. doi:10.1111/risa.12962. <https://www.ncbi.nlm.nih.gov/pubmed/29314143>
20. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use. *BMC Infect Dis* 2018; **18**(1): 165. doi:10.1186/s12879-018-3074-0. <https://www.ncbi.nlm.nih.gov/pubmed/29631539>

2017

21. Thompson KM, Tebbens RJD. How should we prepare for an outbreak of reintroduced live polioviruses? *Future Virology* 2017; **12**(2): 41-4. doi:10.2217/fvl-2016-0131. <https://www.futuremedicine.com/doi/abs/10.2217/fvl-2016-0131>
22. Thompson KM, Duintjer Tebbens RJ. Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes. *J Infect Dis* 2017; **216**(suppl_1): S168-S75. doi:10.1093/infdis/jix128. <https://www.ncbi.nlm.nih.gov/pubmed/28838198>
23. Thompson KM, Duintjer Tebbens RJ. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. *J Infect Dis* 2017; **216**(suppl_1): S176-S82. doi:10.1093/infdis/jix108. <https://www.ncbi.nlm.nih.gov/pubmed/28838194>
24. Thompson KM, Badizadegan ND. Modeling the transmission of measles and rubella to support global management policy analyses and eradication investment cases. *Risk Anal* 2017; **37**(6): 1109-31. doi:10.1111/risa.12831. <https://www.ncbi.nlm.nih.gov/pubmed/28561947>
25. Thompson KM. What will it take to end human suffering from measles? *Lancet Infect Dis* 2017; **17**(10): 1013-4. doi:10.1016/s1473-3099(17)30451-6. <https://www.ncbi.nlm.nih.gov/pubmed/28807626>
26. Thompson KM. Modeling and managing the risks of measles and rubella: a global perspective part II. *Risk Anal* 2017; **37**(6): 1041-51. doi:10.1111/risa.12823. <https://www.ncbi.nlm.nih.gov/pubmed/28471528>
27. Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM. Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems. *Food*



- Environ Virol* 2017; **9**(4): 361-82. doi:10.1007/s12560-017-9314-4.
<https://www.ncbi.nlm.nih.gov/pubmed/28687986>
28. Duintjer Tebbens RJ, Thompson KM. Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy. *Epidemiol Infect* 2017; **145**(2): 217-26. doi:10.1017/S0950268816002302. <https://www.ncbi.nlm.nih.gov/pubmed/27760579>
29. Duintjer Tebbens RJ, Thompson KM. Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use. *MDM Policy Pract* 2017; **2**(1): 2381468317697002. doi:10.1177/2381468317697002. <https://www.ncbi.nlm.nih.gov/pubmed/30288417>
30. Duintjer Tebbens RJ, Thompson KM. Poliovirus vaccination during the endgame: insights from integrated modeling. *Expert Rev Vaccines* 2017; **16**(6): 577-86. doi:10.1080/14760584.2017.1322514. <https://www.ncbi.nlm.nih.gov/pubmed/28437234>
31. Duintjer Tebbens RJ, Thompson KM. Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers. *Vaccine* 2017; **35**(31): 3823-33. doi:10.1016/j.vaccine.2017.05.090. <https://www.ncbi.nlm.nih.gov/pubmed/28606811>

2016

32. Thompson KM, Simons EA, Badizadegan K, Reef SE, Cooper LZ. Characterization of the risks of adverse outcomes following rubella infection in pregnancy. *Risk Anal* 2016; **36**(7): 1315-31. doi:10.1111/risa.12264. <https://www.ncbi.nlm.nih.gov/pubmed/25100307>
33. Thompson KM, Odahowski CL, Goodson JL, Reef SE, Perry RT. Synthesis of evidence to characterize national measles and rubella exposure and immunization histories. *Risk Anal* 2016; **36**(7): 1427-58. doi:10.1111/risa.12454. <https://www.ncbi.nlm.nih.gov/pubmed/26249328>
34. Thompson KM, Odahowski CL. Systematic review of health economic analyses of measles and rubella immunization interventions. *Risk Anal* 2016; **36**(7): 1297-314. doi:10.1111/risa.12331. <https://www.ncbi.nlm.nih.gov/pubmed/25545778>
35. Thompson KM, Odahowski CL. Systematic review of measles and rubella serology studies. *Risk Anal* 2016; **36**(7): 1459-86. doi:10.1111/risa.12430. <https://www.ncbi.nlm.nih.gov/pubmed/26077609>
36. Thompson KM, Odahowski CL. The costs and valuation of health impacts of measles and rubella risk management policies. *Risk Anal* 2016; **36**(7): 1357-82. doi:10.1111/risa.12459. <https://www.ncbi.nlm.nih.gov/pubmed/26249331>
37. Thompson KM, Logan GE, Florida SRT. Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data. *Risk Anal* 2016; **36**(7): 1418-26. doi:10.1111/risa.12424. <https://www.ncbi.nlm.nih.gov/pubmed/26033542>
38. Thompson KM, Kisjes KH. Modeling measles transmission in the North American Amish and options for outbreak response. *Risk Anal* 2016; **36**(7): 1404-17. doi:10.1111/risa.12440. <https://www.ncbi.nlm.nih.gov/pubmed/26103154>
39. Thompson KM, Duintjer Tebbens RJ. Framework for optimal global vaccine stockpile design for vaccine-preventable diseases: application to measles and cholera vaccines as contrasting examples. *Risk Anal* 2016; **36**(7): 1487-509. doi:10.1111/risa.12265. <https://www.ncbi.nlm.nih.gov/pubmed/25109229>
40. Thompson KM, Cochi SL. Modeling and managing the risks of measles and rubella: a global perspective, part I. *Risk Anal* 2016; **36**(7): 1288-96. doi:10.1111/risa.12655. <https://www.ncbi.nlm.nih.gov/pubmed/27424287>
41. Thompson KM. Evolution and use of dynamic transmission models for measles and rubella risk and policy analysis. *Risk Anal* 2016; **36**(7): 1383-403. doi:10.1111/risa.12637. <https://www.ncbi.nlm.nih.gov/pubmed/27277138>



42. Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation. *J Vaccines Vaccin* 2016; **7**(5). doi:10.4172/2157-7560.1000340. <https://www.ncbi.nlm.nih.gov/pubmed/28690915>
43. Simons EA, Reef SE, Cooper LZ, Zimmerman L, Thompson KM. Systematic review of the manifestations of congenital rubella syndrome in infants and characterization of disability-adjusted life years (DALYs). *Risk Anal* 2016; **36**(7): 1332-56. doi:10.1111/risa.12263. <https://www.ncbi.nlm.nih.gov/pubmed/25115193>
44. Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. *Nat Rev Dis Primers* 2016; **2**: 16049. doi:10.1038/nrdp.2016.49. <https://www.ncbi.nlm.nih.gov/pubmed/27411684>
45. Duintjer Tebbens RJ, Thompson KM. Uncertainty and sensitivity analysis of cost assumptions for global long-term poliovirus risk management *J Vaccines Vaccin* 2016; **7**(5): 1000339. doi:10.4172/2157-7560.1000339. <https://www.longdom.org/open-access/uncertainty-and-sensitivity-analysis-of-cost-assumptions-for-global-longtermpoliovirus-risk-management-2157-7560-1000339.pdf>
46. Duintjer Tebbens RJ, Thompson KM. The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management. *Future Microbiol* 2016; **11**: 1549-61. doi:10.2217/fmb-2016-0126. <https://www.ncbi.nlm.nih.gov/pubmed/27831742>
47. Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. *BMC Infect Dis* 2016; **16**: 137. doi:10.1186/s12879-016-1465-7. <https://www.ncbi.nlm.nih.gov/pubmed/27009272>
48. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. *BMC Infect Dis* 2016; **16**: 231. doi:10.1186/s12879-016-1536-9. <https://www.ncbi.nlm.nih.gov/pubmed/27230071>
49. Duintjer Tebbens RJ, Hampton LM, Thompson KM. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use. *BMC Infect Dis* 2016; **16**: 237. doi:10.1186/s12879-016-1537-8. <https://www.ncbi.nlm.nih.gov/pubmed/27246198>

2015

50. Thompson KM, Kalkowska DA, Duintjer Tebbens RJ. Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses. *Vaccine* 2015; **33**(13): 1568-77. doi:10.1016/j.vaccine.2015.02.013. <https://www.ncbi.nlm.nih.gov/pubmed/25701673>
51. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL. Polio eradicators use integrated analytical models to make better decisions. *INFORMS Journal on Applied Analytics* 2015; **45**(1): 5-25. doi:10.1287/inte.2014.0769. <https://pubsonline.informs.org/doi/abs/10.1287/inte.2014.0769>
52. Thompson KM, Duintjer Tebbens RJ. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes. *BMC Infect Dis* 2015; **15**: 374. doi:10.1186/s12879-015-1113-7. <https://www.ncbi.nlm.nih.gov/pubmed/26381878>
53. Thompson KM, Duintjer Tebbens RJ. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission. *BMC Infect Dis* 2015; **15**: 376. doi:10.1186/s12879-015-1116-4. <https://www.ncbi.nlm.nih.gov/pubmed/26382234>
54. Thompson KM. Good news for billions of children who will receive IPV. *Lancet Infect Dis* 2015; **15**(10): 1120-2. doi:10.1016/S1473-3099(15)00099-7. <https://www.ncbi.nlm.nih.gov/pubmed/26289957>
55. Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination. *BMC Infect Dis* 2015; **15**: 66. doi:10.1186/s12879-015-0791-5. <https://www.ncbi.nlm.nih.gov/pubmed/25886823>
56. Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM. Modeling options to manage type 1 wild poliovirus imported into Israel in 2013. *J Infect Dis* 2015; **211**(11): 1800-12. doi:10.1093/infdis/jiu674. <https://www.ncbi.nlm.nih.gov/pubmed/25505296>



57. Duintjer Tebbens RJ, Thompson KM. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs. *BMC Infect Dis* 2015; **15**: 390. doi:10.1186/s12879-015-1114-6. <https://www.ncbi.nlm.nih.gov/pubmed/26404780>
58. Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM. Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria. *PLoS One* 2015; **10**(6): e0130123. doi:10.1371/journal.pone.0130123. <https://www.ncbi.nlm.nih.gov/pubmed/26068928>
59. Duintjer Tebbens RJ, Pallansch MA, Thompson KM. Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs. *BMC Infect Dis* 2015; **15**: 379. doi:10.1186/s12879-015-1115-5. <https://www.ncbi.nlm.nih.gov/pubmed/26382043>
60. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. An economic analysis of poliovirus risk management policy options for 2013-2052. *BMC Infect Dis* 2015; **15**: 389. doi:10.1186/s12879-015-1112-8. <https://www.ncbi.nlm.nih.gov/pubmed/26404632>
61. Berera D, Thompson KM. Medical student knowledge, attitudes, and practices regarding immunization. *J Vaccines Vaccin* 2015; **6**(1): 1000268. doi:10.4172/2157-7560.1000268. <https://www.longdom.org/open-access/medical-student-knowledge-attitudes-and-practices-regarding-immunization-2157-7560.1000268.pdf>

2014

62. Thompson KM, Duintjer Tebbens RJ. Modeling the dynamics of oral poliovirus vaccine cessation. *J Infect Dis* 2014; **210 Suppl 1**: S475-84. doi:10.1093/infdis/jit845. <https://www.ncbi.nlm.nih.gov/pubmed/25316870>
63. Thompson KM, Duintjer Tebbens RJ. National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication. *Expert Rev Vaccines* 2014; **13**(2): 221-34. doi:10.1586/14760584.2014.864563. <https://www.ncbi.nlm.nih.gov/pubmed/24308581>
64. Thompson KM. Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine. *Lancet* 2014; **384**(9953): 1480-2. doi:10.1016/S0140-6736(14)60983-1. <https://www.ncbi.nlm.nih.gov/pubmed/25018123>
65. Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM. Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination. *J Infect Dis* 2014; **210 Suppl 1**: S424-33. doi:10.1093/infdis/jit843. <https://www.ncbi.nlm.nih.gov/pubmed/25316864>
66. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India. *J Infect Dis* 2014; **210 Suppl 1**: S398-411. doi:10.1093/infdis/jit844. <https://www.ncbi.nlm.nih.gov/pubmed/25316861>
67. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. *J Infect Dis* 2014; **210 Suppl 1**: S412-23. doi:10.1093/infdis/jit834. <https://www.ncbi.nlm.nih.gov/pubmed/25316863>
68. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. *J Infect Dis* 2014; **210 Suppl 1**: S485-97. doi:10.1093/infdis/jit838. <https://www.ncbi.nlm.nih.gov/pubmed/25316871>
69. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio immunization campaigns. *BMC Infect Dis* 2014; **14**: 45. doi:10.1186/1471-2334-14-45. <https://www.ncbi.nlm.nih.gov/pubmed/24472313>



2013

70. Thompson KM, Strebel PM, Dabbagh A, Cherian T, Cochi SL. Enabling implementation of the global vaccine action plan: developing investment cases to achieve targets for measles and rubella prevention. *Vaccine* 2013; **31 Suppl 2**: B149-56. doi:10.1016/j.vaccine.2012.11.091. <https://www.ncbi.nlm.nih.gov/pubmed/23598476>
71. Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. *Risk Anal* 2013; **33**(4): 647-63. doi:10.1111/j.1539-6924.2012.01891.x. <https://www.ncbi.nlm.nih.gov/pubmed/22985171>
72. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL. Preradication vaccine policy options for poliovirus infection and disease control. *Risk Anal* 2013; **33**(4): 516-43. doi:10.1111/risa.12019. <https://www.ncbi.nlm.nih.gov/pubmed/23461599>
73. Thompson KM, Duintjer Tebbens RJ, Chagnat CL, Hill A, Costa AJ, Badizadegan K, Namgyal P, Hutubessy RC. Managing cholera as a preventable global threat. *J Vaccines Vaccin* 2013; **4**(183): 1000183. doi:10.4172/2157-7560.1000183. <https://www.longdom.org/open-access/managing-cholera-as-a-preventable-global-threat-2157-7560.1000183.pdf>
74. Thompson KM. Modeling poliovirus risks and the legacy of polio eradication. *Risk Anal* 2013; **33**(4): 505-15. doi:10.1111/risa.12030. <https://www.ncbi.nlm.nih.gov/pubmed/23550939>
75. Hennelly KE, Mannix R, Nigrovic LE, Lee LK, Thompson KM, Monuteaux MC, Proctor M, Schutzman S. Pediatric traumatic brain injury and radiation risks: a clinical decision analysis. *J Pediatr* 2013; **162**(2): 392-7. doi:10.1016/j.jpeds.2012.07.018. <https://www.ncbi.nlm.nih.gov/pubmed/22921827>
76. Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM. Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). *Risk Anal* 2013; **33**(4): 680-702. doi:10.1111/risa.12022. <https://www.ncbi.nlm.nih.gov/pubmed/23470192>
77. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses. *Risk Anal* 2013; **33**(4): 703-49. doi:10.1111/risa.12044. <https://www.ncbi.nlm.nih.gov/pubmed/23521018>
78. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Expert review on poliovirus immunity and transmission. *Risk Anal* 2013; **33**(4): 544-605. doi:10.1111/j.1539-6924.2012.01864.x. <https://www.ncbi.nlm.nih.gov/pubmed/22804479>
79. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM. Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs. *Risk Anal* 2013; **33**(4): 606-46. doi:10.1111/risa.12031. <https://www.ncbi.nlm.nih.gov/pubmed/23550968>

2012

80. Thompson KM, Wallace GS, Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG. Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response. *Public Health Rep* 2012; **127**(1): 23-37. doi:10.1177/003335491212700104. <https://www.ncbi.nlm.nih.gov/pubmed/22298920>
81. Thompson KM, Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation. *Expert Rev Vaccines* 2012; **11**(4): 449-59. doi:10.1586/erv.11.195. <https://www.ncbi.nlm.nih.gov/pubmed/22551030>



82. Thompson KM, Duintjer Tebbens RJ. Development of investment cases for globally-coordinated management of infectious diseases. *J Vaccines Vaccin* 2012; **3**(8): 164. doi:10.4172/2157-7560.1000164. <https://www.longdom.org/open-access/development-of-investment-cases-for-globally-coordinated-management-of-infectious-diseases-2157-7560.1000164.pdf>
83. Thompson KM, Dabbagh A, Strebel PM, Perry R, Gacic-Dobo M, Cochi SL, Cairns L, Reef S. National and global options for managing the risks of measles and rubella. *J Vaccines Vaccin* 2012; **3**: 165. doi:10.4172/2157-7560.1000165. <https://www.longdom.org/open-access/national-and-global-options-for-managing-the-risks-of-measles-and-rubella-2157-7560.1000165>
84. Thompson KM. Valuing prevention as the new paradigm in global health: Managing population immunity for vaccine-preventable diseases. *ICU Management* 2012; **12**(4): 9-11.
85. Thompson KM. The role of risk analysis in polio eradication: modeling possibilities, probabilities and outcomes to inform choices. *Expert Rev Vaccines* 2012; **11**(1): 5-7. doi:10.1586/erv.11.163. <https://www.ncbi.nlm.nih.gov/pubmed/22149700>
86. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. The probability of undetected wild poliovirus circulation after apparent global interruption of transmission. *Am J Epidemiol* 2012; **175**(9): 936-49. doi:10.1093/aje/kwr399. <https://www.ncbi.nlm.nih.gov/pubmed/22459121>
87. Goodson JL, Chu SY, Rota PA, Moss WJ, Featherstone DA, Vijayaraghavan M, Thompson KM, Martin R, Reef S, Strebel PM. Research priorities for global measles and rubella control and eradication. *Vaccine* 2012; **30**(32): 4709-16. doi:10.1016/j.vaccine.2012.04.058. <https://www.ncbi.nlm.nih.gov/pubmed/22549089>
88. Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM. Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics. *Epidemiol Infect* 2011; **139**(6): 836-48. doi:10.1017/S0950268810001676. <https://www.ncbi.nlm.nih.gov/pubmed/20619075>

2007 - 2011

89. Badizadegan K, Thompson KM. Value of information in nonfocal colonic biopsies. *J Pediatr Gastroenterol Nutr* 2011; **53**(6): 679-83. doi:10.1097/MPG.0b013e31822862d9. <https://www.ncbi.nlm.nih.gov/pubmed/21681109>
90. Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM. Optimal vaccine stockpile design for an eradicated disease: application to polio. *Vaccine* 2010; **28**(26): 4312-27. doi:10.1016/j.vaccine.2010.04.001. <https://www.ncbi.nlm.nih.gov/pubmed/20430122>
91. Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM. Economic analysis of the global polio eradication initiative. *Vaccine* 2010; **29**(2): 334-43. doi:10.1016/j.vaccine.2010.10.026. <https://www.ncbi.nlm.nih.gov/pubmed/21029809>
92. Duintjer Tebbens RJ, Thompson KM. Priority shifting and the dynamics of managing eradicable infectious diseases. *Manag Sci* 2009; **55**(4): 650-63. doi:10.1287/mnsc.1080.0965. <https://pubsonline.informs.org/doi/10.1287/mnsc.1080.0965>
93. Thompson KM, Tebbens RJD. Using system dynamics to develop policies that matter: global management of poliomyelitis and beyond. *System Dynamics Review* 2008; **24**(4): 433-49. doi:10.1002/sdr.419. <https://onlinelibrary.wiley.com/doi/abs/10.1002/sdr.419>
94. Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander J, Jafari H, Cochi SL. The risks, costs, and benefits of possible future global policies for managing polioviruses. *Am J Public Health* 2008; **98**(7): 1322-30. doi:10.2105/AJPH.2007.122192. <https://www.ncbi.nlm.nih.gov/pubmed/18511720>
95. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. *Medscape J Med* 2008; **10**(8): 190. <https://www.ncbi.nlm.nih.gov/pubmed/18924642>



96. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM. Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management. *Risk Anal* 2008; **28**(4): 855-76. doi:10.1111/j.1539-6924.2008.01078.x. <https://www.ncbi.nlm.nih.gov/pubmed/18627544>
97. Thompson KM. Reforms for rating media: disclosure, not censorship. *MedGenMed* 2007; **9**(4): 27. <https://www.ncbi.nlm.nih.gov/pubmed/18311377>
98. Lee LK, Thompson KM. Parental survey of beliefs and practices about bathing and water safety and their children: guidance for drowning prevention. *Accid Anal Prev* 2007; **39**(1): 58-62. doi:10.1016/j.aap.2006.06.020. <https://www.ncbi.nlm.nih.gov/pubmed/16920055>

2001 - 2006

99. Thompson KM, Tepichin K, Haninger K. Content and ratings of mature-rated video games. *Arch Pediatr Adolesc Med* 2006; **160**(4): 402-10. doi:10.1001/archpedi.160.4.402. <https://www.ncbi.nlm.nih.gov/pubmed/16585486>
100. Thompson KM, Tebbens RJ. Retrospective cost-effectiveness analyses for polio vaccination in the United States. *Risk Anal* 2006; **26**(6): 1423-40. doi:10.1111/j.1539-6924.2006.00831.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184390>
101. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Caceres VM, Sangruee N, Jafari H, Cochi SL. Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling. *Risk Anal* 2006; **26**(6): 1571-80. doi:10.1111/j.1539-6924.2006.00841.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184398>
102. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. *Risk Anal* 2006; **26**(6): 1541-56. doi:10.1111/j.1539-6924.2006.00843.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184396>
103. Thompson KM. Poliomyelitis and the role of risk analysis in global infectious disease policy and management. *Risk Anal* 2006; **26**(6): 1419-21. doi:10.1111/j.1539-6924.2006.00853.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184389>
104. Tebbens RJ, Sangruee N, Thompson KM. The costs of future polio risk management policies. *Risk Anal* 2006; **26**(6): 1507-31. doi:10.1111/j.1539-6924.2006.00842.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184394>
105. Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. *Risk Anal* 2006; **26**(6): 1471-505. doi:10.1111/j.1539-6924.2006.00827.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184393>
106. Talmor D, Thompson KM, Legedza AT, Nirula R. Predicting severe head injury after light motor vehicle crashes: implications for automatic crash notification systems. *Accid Anal Prev* 2006; **38**(4): 767-71. doi:10.1016/j.aap.2006.01.008. <https://www.ncbi.nlm.nih.gov/pubmed/16530717>
107. Riederer AM, Thompson KM, Fuentes JM, Ford TE. Body weight and water ingestion estimates for women in two communities in the Philippines: the importance of collecting site-specific data. *Int J Hyg Environ Health* 2006; **209**(1): 69-80. doi:10.1016/j.ijheh.2005.08.002. <https://www.ncbi.nlm.nih.gov/pubmed/16373204>
108. Lee LK, Mao C, Thompson KM. Demographic factors and their association with outcomes in pediatric submersion injury. *Acad Emerg Med* 2006; **13**(3): 308-13. doi:10.1197/j.aem.2005.10.012. <https://www.ncbi.nlm.nih.gov/pubmed/16495427>
109. de Gourville E, Duintjer Tebbens RJ, Sangruee N, Pallansch MA, Thompson KM. Global surveillance and the value of information: the case of the global polio laboratory network. *Risk Anal* 2006; **26**(6): 1557-69. doi:10.1111/j.1539-6924.2006.00845.x. <https://www.ncbi.nlm.nih.gov/pubmed/17184397>



110. Bruce Aylward R, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D. Risk management in a polio-free world. *Risk Anal* 2006; **26**(6): 1441-8. doi:10.1111/j.1539-6924.2006.00840.x.
<https://www.ncbi.nlm.nih.gov/pubmed/17184391>
111. Wendler D, Belsky L, Thompson KM, Emanuel EJ. Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. *JAMA* 2005; **294**(7): 826-32. doi:10.1001/jama.294.7.826. <https://www.ncbi.nlm.nih.gov/pubmed/16106008>
112. Thompson KM. Addicted media: substances on screen. *Child Adolesc Psychiatr Clin N Am* 2005; **14**(3): 473-89, ix. doi:10.1016/j.chc.2005.02.007. <https://www.ncbi.nlm.nih.gov/pubmed/15936669>
113. Thompson KM. Kids and media: learning happens. *MedGenMed* 2005; **7**(2): 47. <https://www.ncbi.nlm.nih.gov/pubmed/16369425>
114. Duintjer Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Sutter RW, Thompson KM. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. *Am J Epidemiol* 2005; **162**(4): 358-72. doi:10.1093/aje/kwi206. <https://www.ncbi.nlm.nih.gov/pubmed/16014773>
115. Yokota F, Gray G, Hammitt JK, Thompson KM. Tiered chemical testing: a value of information approach. *Risk Anal* 2004; **24**(6): 1625-39. doi:10.1111/j.0272-4332.2004.00555.x. <https://www.ncbi.nlm.nih.gov/pubmed/15660617>
116. Thompson KM, Yokota F. Violence, sex and profanity in films: correlation of movie ratings with content. *MedGenMed* 2004; **6**(3): 3. <https://www.ncbi.nlm.nih.gov/pubmed/15520625>
117. Thompson KM. Changes in children's exposure as a function of age and the relevance of age definitions for exposure and health risk assessment. *MedGenMed* 2004; **6**(3): 2. <https://www.ncbi.nlm.nih.gov/pubmed/15520624>
118. Haninger K, Thompson KM. Content and ratings of teen-rated video games. *JAMA* 2004; **291**(7): 856-65. doi:10.1001/jama.291.7.856. <https://www.ncbi.nlm.nih.gov/pubmed/14970065>
119. Haninger K, Ryan MS, Thompson KM. Violence in teen-rated video games. *MedGenMed* 2004; **6**(1): 1. <https://www.ncbi.nlm.nih.gov/pubmed/15208514>
120. Thompson KM. The role of bath seats in unintentional infant bathtub drowning deaths. *MedGenMed* 2003; **5**(1): 36. <https://www.ncbi.nlm.nih.gov/pubmed/12827097>
121. Thompson KM. How much do kids count in corporate board rooms? Results from the first survey of Fortune 1000 companies. *MedGenMed* 2003; **5**(1): 37. <https://www.ncbi.nlm.nih.gov/pubmed/12827098>
122. Sangruejee N, Duintjer Tebbens RJ, Caceres VM, Thompson KM. Policy decision options during the first 5 years following certification of polio eradication. *MedGenMed* 2003; **5**(4): 35. <https://www.ncbi.nlm.nih.gov/pubmed/14745382>
123. Thompson KM, Segui-Gomez M, Graham JD. Validating benefit and cost estimates: the case of airbag regulation. *Risk Anal* 2002; **22**(4): 803-11. doi:10.1111/0272-4332.00070. <https://www.ncbi.nlm.nih.gov/pubmed/12224752>
124. Thompson KM, Haninger K. Violence in E-rated video games. *JAMA* 2001; **286**(5): 591-8. doi:10.1001/jama.286.5.591. <https://www.ncbi.nlm.nih.gov/pubmed/11476663>
125. Juberg DR, Alfano K, Coughlin RJ, Thompson KM. An observational study of object mouthing behavior by young children. *Pediatrics* 2001; **107**(1): 135-42. doi:10.1542/peds.107.1.135. <https://www.ncbi.nlm.nih.gov/pubmed/11134447>

1991 - 2001

126. Yokota F, Thompson KM. Violence in G-rated animated films. *JAMA* 2000; **283**(20): 2716-20. doi:10.1001/jama.283.20.2716. <https://www.ncbi.nlm.nih.gov/pubmed/10819958>
127. Thompson KM, Segui-Gomez M, Graham JD. Validating analytical judgments: the case of the airbag's lifesaving effectiveness. *Reliability Engineering & System Safety* 1999; **66**(1): 57-68. doi:10.1016/S0951-8320(99)00019-8. <https://www.sciencedirect.com/science/article/pii/S0951832099000198>



128. Graham JD, Goldie SJ, Segui-Gomez M, Thompson KM, Nelson T, Glass R, Simpson A, Woerner LG. Reducing risks to children in vehicles with passenger airbags. *Pediatrics* 1998; **102**(1): e3. doi:10.1542/peds.102.1.e3. <https://www.ncbi.nlm.nih.gov/pubmed/9651455>
129. Graham JD, Thompson KM, Goldie SJ, Segui-Gomez M, Weinstein MC. The cost-effectiveness of air bags by seating position. *JAMA* 1997; **278**(17): 1418-25. doi:10.1001/jama.1997.03550170048031. <https://www.ncbi.nlm.nih.gov/pubmed/9356000>
130. Thompson KM, Burmaster DE. Parametric distributions for soil ingestion by children. *Risk Anal* 1991; **11**(2): 339-42. doi:10.1111/j.1539-6924.1991.tb00610.x. <https://www.ncbi.nlm.nih.gov/pubmed/1876729>